A Rare Case of Ixazomib-Induced Cutaneous Necrotizing Vasculitis in a Patient with Relapsed Myeloma

Ixazomib is the only oral proteasome inhibitor used in relapsed/refractory myeloma. Cutaneous side effects due to ixazomib have been documented in the literature; however, cutaneous necrotizing vasculitis is extremely rare. We describe a case of a 74-year-old man with relapsed multiple myeloma who w...

Descripción completa

Detalles Bibliográficos
Autores principales: Katz, Heather, Shenouda, Mina, Dahshan, Deena, Sonnier, George, Lebowicz, Yehuda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855061/
https://www.ncbi.nlm.nih.gov/pubmed/31781426
http://dx.doi.org/10.1155/2019/6061484
_version_ 1783470343728398336
author Katz, Heather
Shenouda, Mina
Dahshan, Deena
Sonnier, George
Lebowicz, Yehuda
author_facet Katz, Heather
Shenouda, Mina
Dahshan, Deena
Sonnier, George
Lebowicz, Yehuda
author_sort Katz, Heather
collection PubMed
description Ixazomib is the only oral proteasome inhibitor used in relapsed/refractory myeloma. Cutaneous side effects due to ixazomib have been documented in the literature; however, cutaneous necrotizing vasculitis is extremely rare. We describe a case of a 74-year-old man with relapsed multiple myeloma who was started on ixazomib, lenalidomide, and dexamethasone. He developed several skin lesions that were biopsied and revealed cutaneous necrotizing vasculitis. Ixazomib was held with resolution of the vasculitic lesions and restarted with dexamethasone to 20 mg on the day of treatment and 20 mg dose the day after treatment.
format Online
Article
Text
id pubmed-6855061
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-68550612019-11-28 A Rare Case of Ixazomib-Induced Cutaneous Necrotizing Vasculitis in a Patient with Relapsed Myeloma Katz, Heather Shenouda, Mina Dahshan, Deena Sonnier, George Lebowicz, Yehuda Case Rep Hematol Case Report Ixazomib is the only oral proteasome inhibitor used in relapsed/refractory myeloma. Cutaneous side effects due to ixazomib have been documented in the literature; however, cutaneous necrotizing vasculitis is extremely rare. We describe a case of a 74-year-old man with relapsed multiple myeloma who was started on ixazomib, lenalidomide, and dexamethasone. He developed several skin lesions that were biopsied and revealed cutaneous necrotizing vasculitis. Ixazomib was held with resolution of the vasculitic lesions and restarted with dexamethasone to 20 mg on the day of treatment and 20 mg dose the day after treatment. Hindawi 2019-10-20 /pmc/articles/PMC6855061/ /pubmed/31781426 http://dx.doi.org/10.1155/2019/6061484 Text en Copyright © 2019 Heather Katz et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Katz, Heather
Shenouda, Mina
Dahshan, Deena
Sonnier, George
Lebowicz, Yehuda
A Rare Case of Ixazomib-Induced Cutaneous Necrotizing Vasculitis in a Patient with Relapsed Myeloma
title A Rare Case of Ixazomib-Induced Cutaneous Necrotizing Vasculitis in a Patient with Relapsed Myeloma
title_full A Rare Case of Ixazomib-Induced Cutaneous Necrotizing Vasculitis in a Patient with Relapsed Myeloma
title_fullStr A Rare Case of Ixazomib-Induced Cutaneous Necrotizing Vasculitis in a Patient with Relapsed Myeloma
title_full_unstemmed A Rare Case of Ixazomib-Induced Cutaneous Necrotizing Vasculitis in a Patient with Relapsed Myeloma
title_short A Rare Case of Ixazomib-Induced Cutaneous Necrotizing Vasculitis in a Patient with Relapsed Myeloma
title_sort rare case of ixazomib-induced cutaneous necrotizing vasculitis in a patient with relapsed myeloma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855061/
https://www.ncbi.nlm.nih.gov/pubmed/31781426
http://dx.doi.org/10.1155/2019/6061484
work_keys_str_mv AT katzheather ararecaseofixazomibinducedcutaneousnecrotizingvasculitisinapatientwithrelapsedmyeloma
AT shenoudamina ararecaseofixazomibinducedcutaneousnecrotizingvasculitisinapatientwithrelapsedmyeloma
AT dahshandeena ararecaseofixazomibinducedcutaneousnecrotizingvasculitisinapatientwithrelapsedmyeloma
AT sonniergeorge ararecaseofixazomibinducedcutaneousnecrotizingvasculitisinapatientwithrelapsedmyeloma
AT lebowiczyehuda ararecaseofixazomibinducedcutaneousnecrotizingvasculitisinapatientwithrelapsedmyeloma
AT katzheather rarecaseofixazomibinducedcutaneousnecrotizingvasculitisinapatientwithrelapsedmyeloma
AT shenoudamina rarecaseofixazomibinducedcutaneousnecrotizingvasculitisinapatientwithrelapsedmyeloma
AT dahshandeena rarecaseofixazomibinducedcutaneousnecrotizingvasculitisinapatientwithrelapsedmyeloma
AT sonniergeorge rarecaseofixazomibinducedcutaneousnecrotizingvasculitisinapatientwithrelapsedmyeloma
AT lebowiczyehuda rarecaseofixazomibinducedcutaneousnecrotizingvasculitisinapatientwithrelapsedmyeloma

Ejemplares similares